Explanipedia

Defining Optimally Safe and Effective Blood Levels of Hydroxychloroquine in Lupus: An Important Step toward Precision Drug Monitoring Open

Shivani Garg, Benoı̂t Blanchet, Yann Nguyen, Fauzia Osman, Ada Clarke , et al. · 2025

Background Using hydroxychloroquine (HCQ) dose of 5 mg/kg/day in systemic lupus erythematosus (SLE) is associated with a higher risk of flares; HCQ blood level monitoring could be a better way to adjust HCQ dose. We studied the upper thres…

The CARMEN-France registry of adult patients with immune thrombocytopenia and autoimmune hemolytic anemia in France Open

Guillaume Moulis, Marc Michel, Bernard Bonnotte, Bertrand Godeau, Félix Ackermann , et al. · 2024

O24 <i>APOL1</i> genotype is a major determinant of lupus nephritis severity in patients of African ancestry Open

Carole Burger, Nicolas Bénichou, Céline Narjoz, N. Costedoat‐Chalumeau, Véronique Le Guern , et al. · 2024

Objective G1 and G2 polymorphisms of APOL1 gene, exclusively found among patients of African ancestry, have been associated with chronic kidney disease (CKD) and collapsing glomerulopathy. We investigated their impact on lupus nephr…

#3155 APOL1 GENOTYPE IS A MAJOR DETERMINANT OF LUPUS NEPHRITIS SEVERITY IN PATIENTS OF AFRICAN ANCESTRY Open

Carole Burger, Nicolas Bénichou, Céline Narjoz, N. Costedoat‐Chalumeau, Véronique Le Guern , et al. · 2023

Background and Aims Two polymorphisms of APOL1 gene, G1 and G2, exclusively found among patients of African ancestry, have been associated with chronic kidney disease (CKD) and end-stage kidney disease (ESKD)1. These high-risk polymorphism…

POS0722 CLONAL HEMATOPOIESIS OF INDETERMINATE POTENTIAL AND ACCELERATED ATHEROSCLEROSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS (HEMATOPLUS STUDY) Open

C. David, N. Costedoat‐Chalumeau, Nicolas Duployez, Drifa Belhadi, V. Leguern , et al. · 2022

Soluble CD163 and incident cardiovascular events in patients with systemic lupus erythematosus: An observational cohort study Open

C. David, N. Costedoat‐Chalumeau, Drifa Belhadi, Cédric Laouénan, Anne Boutten , et al. · 2022

International audience

Clonal haematopoiesis of indeterminate potential and cardiovascular events in systemic lupus erythematosus (HEMATOPLUS study) Open

C. David, Nicolas Duployez, Philippine Eloy, Drifa Belhadi, J. Chezel , et al. · 2022

Objective The detection of somatic mutations among the genes of myeloid cells in asymptomatic patients—defining clonal haematopoiesis of indeterminate potential (CHIP)—is associated with a predisposition to cardiovascular events (CVEs) in …

SAT0201 ASSOCIATION OF CARDIAC TROPONIN T MEASURED WITH A HIGHLY SENSITIVE ASSAY WITH CARDIOVASCULAR EVENTS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (TROPOPLUS STUDY) Open

J. Chezel, N. Costedoat‐Chalumeau, Diane Rouzaud, Véronique Le Guern, Camille Gobeaux , et al. · 2020

AB0140 BAFF NEUTRALIZATION HAS JANUS-FACED EFFECT ON ATHEROSCLEROSIS ASSOCIATED WITH SYSTEMIC LUPUS ERYTHEMATOSUS Open

Fanny Saidoune, Nicolas Charles, J. Chezel, Brigitte Escoubet, T. Papo , et al. · 2020

Risk factors for hydroxychloroquine retinopathy in systemic lupus erythematosus: a case–control study with hydroxychloroquine blood-level analysis Open

Tiphaine Lenfant, S. Ben Salah, Gaëlle Leroux, Elodie Bousquet, Véronique Le Guern , et al. · 2020

Objective HCQ is an essential medication in SLE, proven to lengthen survival and reduce flares. Its use, however, is limited by its rare but severe ophthalmological complications. Here, we aimed to analyse factors associated with HCQ retin…

Soluble CD163 is a biomarker for accelerated atherosclerosis in systemic lupus erythematosus patients at apparent low risk for cardiovascular disease Open

C. David, Gillian Divard, Rachid Abbas, Brigitte Escoubet, J. Chezel , et al. · 2019

Objective: This study aimed to determine whether sCD163, a soluble macrophage marker up-regulated in numerous inflammatory disorders, is predictive of accelerated atherosclerosis associated with systemic lupus erythematosus (SLE). <…

J. Chezel YOU? Author Swipe